It is an antihistaminic drug which also has anticholinergic, sedative, anti-5HT and vasodilator actions.
Antihistaminics, anti-emetics and antivertigo preparations
Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking calcium channels. Cinnarizine increases erythrocyte deformability and decreases blood viscosity in vitro. Cinarizine inhibits stimulation of the vestibular system.
Control of vestibular symptoms of both peripheral and central origin and of labyrinthine disorders including vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting.
Prophylaxis of motion sickness.
Adjunct therapy for symptoms of peripheral arterial disease.
DOSAGE AND ADMINISTRATION
Vestibular disorders: Adults and children over the age of 12 years -25 to 75 mg tablets three times daily.
Motion Sickness: Adults : 25 mg may be taken 2 hours before the start of the journey and 12.5 mg and 25 mg may be repeated every 8 hours during the journey when necessary.
Children 5 to 12 years: 12.5mg (half a tablet) three times daily when necessary.
In patients with known hypersensitivity to cinnarizine.
Use in pregnancy: The safety of cinnarizine tablets in pregnant and lactating women has not been established.
Precautions: In patients with Parkinson’s disease, cinnarizine should only be given if the advantages outweigh the possible risk of aggravating the disease.
The most common antihistaminic side-effect of cinnarizine is sedation which can vary from slight drowsiness to deep sleep, and including inability to concentrate, lassitude, dizziness, and inco-ordination. Sedative effects, when they occur, may diminish after a few days.
Other side effects include gastro-intestinal disturbances such as nausea, vomiting, diarrhea or constipation, anorexia or increased appetite and epigastric pain. Somnolence and gastro-intestinal disturbances are usually transient and may often be prevented by achieving the optimum dosage gradually.
In elderly people cases of aggravation or an appearance of extrapyramidal symptoms sometimes associated with depressive feelings have been described during prolonged therapy. The treatment should be discontinued in such cases.
Cinnarizine may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, tricyclic antidepressants, sedative and tranquilisers.
The side effects of anticholinergic substances such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of antihistamines Monoamine-oxidase inhibitors may enhance the antimuscarinic effects of antihistamine.
This medicine may lead to drowsiness and impaired concentration, which may be aggravated by simultaneous intake of alcohol or other central nervous system depressants.
Tablets 25mg x 10’s
4 x 5 x 10’s